STOCK TITAN
  1. Home
  2. News
  3. MOTS

MOTUS GI HOLDINGS INC - MOTS STOCK NEWS

Welcome to our dedicated page for MOTUS GI HOLDINGS news (Ticker: MOTS), a resource for investors and traders seeking the latest updates and insights on MOTUS GI HOLDINGS stock.

Motus GI Holdings, Inc. (NASDAQ: MOTS) is a medical technology company headquartered in the United States with subsidiaries in the U.S. and Israel. The company is committed to enhancing endoscopy outcomes, reducing costs, and improving patient experiences. A primary focus of Motus GI is the development and commercialization of the Pure-Vu® System.

The Pure-Vu® System is a medical device designed to improve the colonoscopy experience by aiding in the early detection and prevention of colorectal cancer and other diseases of the colon and rectum. This innovative system, which has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval in Europe, integrates with standard colonoscopes. It facilitates cleaning of a poorly prepared colon during the colonoscopy procedure while maintaining the standard workflow and techniques.

Recent achievements of Motus GI include strengthening their market presence through strategic partnerships and ongoing projects aimed at enhancing the Pure-Vu® System’s functionality and reach. The company continues to focus on securing additional regulatory approvals, expanding its market base, and improving its financial performance.

News

Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update

Rhea-AI Summary

Motus GI Holdings, a medical technology company, reported its Q1 2024 financial results and corporate updates. The U.S. launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system doubled the number of active customers, with 100% adopting the system independently. The company appointed an investment bank to explore strategic alternatives to boost commercialization and stockholder value. Revenues for Q1 2024 increased to $64,000 from $56,000 in Q1 2023, primarily from disposable sleeve reorders. Despite this, the net loss deepened to $7.6 million from $4.4 million year-over-year. Cash and equivalents stood at $4.9 million as of March 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.05%
Tags
earnings
-
News

Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Motus GI Holdings, Inc. (MOTS) initiated a U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system, leading to successful UGI procedures at top hospital systems. The Company aims to accelerate commercialization through strategic partnerships. An infusion of $2.7M from outstanding warrants extended the cash runway till Q4 2024. Financially, revenue declined from $109,000 in Q4 2022 to $64,000 in Q4 2023, with a net loss of $2.8 million. However, the Company reported $5.0 million in cash and cash equivalents as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.54%
Tags
earnings
-
News

EndoSound™ Inc., Appoints Medical Device Commercial Leader Scott Aldrich Jr as Chief Executive Officer

Rhea-AI Summary
EndoSound appoints Scott Aldrich Jr as CEO, leveraging his expertise from MotusGI for EVS launch. The company aims for sustainable growth in the medical technology sector.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
management
News

Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds

Rhea-AI Summary
Motus GI Holdings, Inc. announced the immediate exercise of an outstanding Series B common stock purchase warrant, resulting in gross proceeds of approximately $2.7 million. The investor exercised the warrant at a revised price of $0.925 per share and received two new unregistered warrants. The transaction is expected to close by February 26, 2024, and the net proceeds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.18%
Tags
none
-
News

Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract

Rhea-AI Summary
Motus GI Holdings, Inc. announces the issuance of a new patent by the USPTO for their Colon Cleaning System with Automatic Self-Purging Feature, aimed at improving endoscopic outcomes. The patent covers the automated pressure management and self-purging feature of the Pure-Vu system, enhancing physician experience by avoiding procedure delays. This innovation addresses common issues in inpatient endoscopy, reducing the need for delayed, aborted, and repeat procedures, ultimately benefiting both patients and the healthcare system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
68.71%
Tags
none
-
News

Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders

Rhea-AI Summary
Motus GI Holdings, Inc. adjourned its special meeting of stockholders to allow more time for voting on a proposal outlined in the Proxy Statement filed with the SEC. The meeting will reconvene on March 7, 2024, with the original record date remaining unchanged. Stockholders are encouraged to vote 'FOR' the proposal, with previously submitted proxies still valid.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
none
News

Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation

Rhea-AI Summary
Motus GI Holdings, Inc. announced positive data from a study of the second generation Pure-Vu System in the United European Gastroenterology journal. The study showed improved bowel cleansing in patients with previous poor preparation, reducing the need for repeat colonoscopies and clinical admissions. The study met its primary and secondary endpoints, with a high rate of adequate cleansing and cecal intubation. The next generation Pure-Vu System, with FDA clearance, features key enhancements addressing limitations of the previous model.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-25.73%
Tags
none
-
News

 Motus GI Holdings, Inc. Announces Pricing of $5.0 Million Public Offering

Rhea-AI Summary
Motus GI Holdings, Inc. (Nasdaq: MOTS) announced a public offering of 3,333,334 shares of common stock, Series A common warrants, and Series B common warrants at a combined public offering price of $1.50 per share, resulting in approximately $5.0 million in gross proceeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-39.07%
Tags
offering
-
News

Motus GI Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Motus GI Holdings, Inc. (NASDAQ: MOTS) reported its financial results for Q3 2023, announcing the FDA clearance for the Pure-Vu® EVS Gastro and Gen 4 Colon system. The company aims to initiate broader market introductions by the end of 2023. The Pure-Vu EVS Gastro targets the Upper GI market, addressing high unmet clinical need, including approximately 400,000 cases of upper GI bleeds per year in the U.S. The company is exploring strategic and financing alternatives to accelerate commercialization of the Pure-Vu System and maximize stockholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.75%
Tags
earnings
News

Motus GI Announces First Upper GI Patient Procedure for FDA Cleared Pure-Vu® EVS Gastro

Rhea-AI Summary
Motus GI Holdings, Inc. (NASDAQ: MOTS) announced the successful use of Pure-Vu EVS Gastro in the first procedure since FDA clearance, addressing the high unmet clinical need in the Upper GI market, with approximately 400,000 cases of upper GI bleeds per year in the U.S. The device provides enhanced irrigation and suction capabilities, targeting blood, blood clots, and other debris in the upper GI tract.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.71%
Tags
none

FAQ

What is the current stock price of MOTUS GI HOLDINGS (MOTS)?

The current stock price of MOTUS GI HOLDINGS (MOTS) is $0.0251 as of October 15, 2024.

What is the market cap of MOTUS GI HOLDINGS (MOTS)?

The market cap of MOTUS GI HOLDINGS (MOTS) is approximately 435.1K.

What is Motus GI Holdings, Inc.?

Motus GI Holdings, Inc. is a U.S.-based medical technology company focused on improving endoscopy outcomes and patient experiences.

What product is Motus GI known for?

Motus GI is known for the Pure-Vu® System, a device designed to improve the colonoscopy process.

What does the Pure-Vu® System do?

The Pure-Vu® System aids in cleaning a poorly prepared colon during a colonoscopy, facilitating early disease detection and prevention while preserving standard procedural techniques.

Is the Pure-Vu® System approved for use?

Yes, the Pure-Vu® System has received 510(k) clearance from the U.S. FDA and CE Mark approval in Europe.

Where is Motus GI Holdings, Inc. located?

Motus GI Holdings, Inc. is headquartered in the United States with subsidiaries in the U.S. and Israel.

What are the recent achievements of Motus GI?

Recent achievements include market expansion efforts, strategic partnerships, and ongoing development projects for the Pure-Vu® System.

What is the primary focus of Motus GI's current projects?

Current projects are focused on enhancing the Pure-Vu® System’s functionality and securing more regulatory approvals.

How does the Pure-Vu® System integrate with colonoscopes?

The Pure-Vu® System integrates with standard colonoscopes to clean the colon during the procedure, maintaining the standard workflow and techniques.

How does Motus GI contribute to healthcare cost reduction?

By improving the colonoscopy process and reducing the need for repeat procedures, Motus GI helps lower healthcare costs.

Who can I contact for investor information about Motus GI?

For investor information, contact Troy Williams at LifeSci Advisors via phone at (518) 221-0106 or email at twilliams@lifesciadvisors.com.

Stock MOTS logo
MOTUS GI HOLDINGS INC

OTC:MOTS

MOTS Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

MOTS Stock Data

435.11k
6.33M
0.9%
0.01%
0.45%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
FT. LAUDERDALE